Introduction
============

Osteosarcoma is one of the most common types of primary malignant bone cancer and is characterized by tumor cells directly forming osteoid tissue or immature bone ([@b1-mmr-19-02-1128]--[@b3-mmr-19-02-1128]). Epidemiological study has indicated a bimodal age distribution for osteosarcoma, with pubescent adolescents undergoing a rapid growth period at the greatest risk ([@b4-mmr-19-02-1128]). While effective methods, including primary tumor excision, adjuvant radiotherapy and chemotherapy, have been widely adopted to improve osteosarcoma survival, the prognosis remains poor ([@b5-mmr-19-02-1128]). The 5-year survival rate is \>20% in high-risk patients treated with surgery alone ([@b6-mmr-19-02-1128]), with an increase to a 30--40% survival rate when surgery is combined with adjuvant therapies, radiation or chemotherapy ([@b7-mmr-19-02-1128]). Therefore, the identification of an effective prognostic factor able to optimize treatment and supply a novel therapeutic target to improve the clinical outcome for patients with osteosarcoma is required.

Long non-coding RNAs (lncRNAs) are \>200 nucleotides and lack an open reading frame, and therefore are unable to be translated into a protein ([@b8-mmr-19-02-1128]). With the expansion of gene research, lncRNAs have been identified to serve critical roles in a variety of cellular processes, including gene and protein regulation, transcription and post-transcription ([@b9-mmr-19-02-1128]--[@b11-mmr-19-02-1128]). The roles of lncRNAs in tumor-associated processes have also been widely examined, with certain lncRNAs having been demonstrated to be associated with histological grade in several tumor types ([@b9-mmr-19-02-1128]). Furthermore, increasing evidence has suggested that lncRNAs may serve as useful prognostic biomarkers for certain tumors, including non-small cell lung cancer ([@b12-mmr-19-02-1128]), metastatic breast cancer ([@b13-mmr-19-02-1128]) and hepatocellular carcinomas ([@b14-mmr-19-02-1128]). Previous studies have focused on the roles of lncRNAs in osteosarcoma prognosis: A specific lncRNA, taurine upregulated gene 1, was suggested to contribute to human osteosarcoma tumorigenesis by regulating POU domain class 2 transcription factor 1 expression ([@b15-mmr-19-02-1128]). In addition, overexpression of the lncRNA BRAF-activated noncoding RNA was observed in osteosarcomas, with an increased expression associated with advanced clinical stage, distant metastasis and large tumor size ([@b16-mmr-19-02-1128]). However, a reliable and effective risk assessment model for osteosarcoma prognosis is required.

In the present study, human osteosarcoma expression profiles were downloaded to screen prognosis-associated lncRNAs. Next, a risk assessment system was constructed based on the expressions of prognosis-associated lncRNAs, with the associated regression coefficients used as the weight. Survival analysis for the risk assessment model was conducted using a training set and validation set. Concomitantly, the risk value of each sample was calculated based on the risk score equation. Independent osteosarcoma prognostic factors and correlations between risk score and clinical features were also examined. Additionally, differentially expressed genes associated with the lncRNAs in the risk assessment model were identified, and functional enrichment was performed. The present study aimed to identify a novel risk assessment model for osteosarcoma prognosis, and thereby aid in patient drug selections and adjustments.

Materials and methods
=====================

### Data and grouping

Human osteosarcoma-associated expression profiles were downloaded from the NCBI Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>) and EBI ArrayExpress (<https://www.ebi.ac.uk/arrayexpress/>) databases. The expression data were included when meet the following criteria: i) The osteosarcoma sample data must contain clinical information and a survival prognosis; and ii) the annotation platform must contain lncRNA annotation information or provide complete sequence detection of the probe reporter. Ultimately, two data sets, GSE21257 (n=53) and GSE39055 (n=37), were identified and obtained using the GPL10295 human-6 v2.0 (using nuIDs as identifier; Illumina, Inc., San Diego, CA, USA) and GPL14951 HumanHT-12 WG-DASL v4.0 R2 expression beadchips (Illumina, Inc.), respectively. The GSE21257 set was selected as the training set, and the GSE39055 was set as the validation set. The clinical data for these two data sets are summarized in [Table I](#tI-mmr-19-02-1128){ref-type="table"}. The lncRNAs in these two data sets were analyzed using Basic Local Alignment Search Tool and a human genome reference sequence (UCSC hg19; <http://hgdownload.soe.ucsc.edu/downloads.html>).

### Screening for significantly differentially expressed lncRNAs

The 53 training set samples (GSE21257) were divided into a bad prognosis group (survival time \<36 months; n=17) or good prognosis group (alive, survival time ≥60 months; n=21). The expression levels of lncRNAs between these two groups were then compared to identify significantly differentially expressed lncRNAs by using a Student\'s t-test or Wilcoxon rank test in R v3.1.0 with the thresholds of false discovery rate (FDR) \<0.05 and log~2~ fold change (FC) \>0.263. LncRNAs revealed to be significantly differentially expressed using these two cut-offs were selected for two-way hierarchical clustering and subsequent analysis.

### Screening for prognosis-associated lncRNAs

To screen prognosis-associated lncRNAs, significantly differentially expressed lncRNAs selected from the training set (53 osteosarcoma samples) were examined via Cox regression analysis (univariate and multivariate) in R v3.1.0 (<https://www.r-project.org/>) as described previously ([@b17-mmr-19-02-1128]). P\<0.05 obtained by log-rank test was set as the cut-off criterion.

### Establishing a risk assessment model

To establish a risk assessment system, the obtained prognosis-associated lncRNAs were evaluated using a multivariate Cox regression with the regression coefficients (β) used as the weight. The risk value for each sample was obtained using the following equation: Risk score=β~lncRNA1~ xexpr~lncRNA1~+β~lncRNA2~xexpr~lncRNA2~+···+β~lncRNAn~xexpr~lncRNAn~. The survival risk of cancer in the validation set was assessed using the β-value acquired from the training set.

### Evaluating the risk assessment model

The samples in the validation set were divided into high risk and low risk groups according to the median risk scores calculated in the risk assessment model. The median value was included in the low risk group. Kaplan-Meier survival curve analysis was used to estimate the overall survival (OS) rates for patients in the high risk and low risk groups, followed by a log-rank test ([@b18-mmr-19-02-1128]), which was used to assess the survival differences between the high-risk and the low-risk groups. P\<0.05 was considered to indicate a statistically significant difference. Furthermore, a ROC curve was used to evaluate the classification efficiency of the obtained risk assessment model. The expression distributions of the selected lncRNAs were also analyzed in the training and validation sets.

### Correlation between the risk assessment model and clinical features

Associations between prognosis and clinical features, which include risk score, age, sex, grade and tumor metastasis, were evaluated using univariate and multivariate Cox regression analyses. Furthermore, hierarchical analysis was also performed using clinical features that were significantly associated with the risk score. Associations between the different risk groups and the survival prognosis were analyzed under the same clinical condition.

### Identifying prognosis-associated genes and functional enrichment analysis

The genes regulated by the significantly differentially expressed lncRNA were obtained using MEM software (<http://biit.cs.ut.ee/mem/>) ([@b19-mmr-19-02-1128],[@b20-mmr-19-02-1128]). Subsequently, the differentially expressed genes between high-risk group and low-risk group in the training set were identified with the thresholds of \|log FC\|\>0.5 and FDR\<0.05 using Limma ([@b21-mmr-19-02-1128],[@b22-mmr-19-02-1128]). These differentially expressed were considered prognosis-associated genes.

In order to identify the biological processes and signaling pathways that involved these prognosis-associated genes, the Database for Annotation, Visualization and Integrated Discovery (<https://david.ncifcrf.gov/>) was used to perform Gene Ontology (<http://geneontology.org/>) analysis, and the Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.genome.jp/kegg/>) database was utilized for enrichment analysis with the cut-off of P\<0.05.

Results
=======

### Screened differentially expressed lncRNAs

A total of 233 differentially expressed lncRNAs were identified using the Student\'s t-test ([Fig. 1A](#f1-mmr-19-02-1128){ref-type="fig"}) and 298 were identified using the Wilcoxon rank test ([Fig. 1B](#f1-mmr-19-02-1128){ref-type="fig"}). The 211 overlapping lncRNAs identified by Student\'s t-test and Wilcoxon rank test were selected for subsequent analysis ([Fig. 1C](#f1-mmr-19-02-1128){ref-type="fig"}). The two-way hierarchical clustering based on these 211 lncRNAs indicated significant differences between the bad and good prognosis groups ([Fig. 1D](#f1-mmr-19-02-1128){ref-type="fig"}).

### Construction of the lncRNA risk assessment model

In the training set, 84 out of the 211 differentially expressed lncRNAs were identified to be associated with the survival prognosis (P\<0.05). Next, 9 lncRNAs (CH17-360D5.2, LINC00987, LINC01526, RP11-15A1.3, RP11-213H15.1, RP11-218F4.1, RP11-242F11.2, RP11-411H5.1 and RP11-834C11.5) from the 84 prognosis-associated lncRNAs were additionally screened via a multiple Cox regression analysis (P\<0.05; [Table II](#tII-mmr-19-02-1128){ref-type="table"}). All samples in training set were divided into low expression group (£ median value) and high expression group (\> median value) based on the expression levels of these 9 individual lncRNAs, separately. The Kaplan-Meier survival curve analysis revealed that the samples with low expression of RP11-411H5.1, RP11-834C11.5 or LINC00987 had significantly increased survival ratio ([Fig. 2](#f2-mmr-19-02-1128){ref-type="fig"}). Samples with increased expression of LINC01526, RP11-15A1.3, RP11-213H15.1, RP11-218F4.1, RP11-242F11.2 or CH17-360D5.2 exhibited markedly increased survival ratios ([Fig. 2](#f2-mmr-19-02-1128){ref-type="fig"}).

A risk assessment model was established based on these 9 lncRNAs according to the following formula: Risk score= (−2.0368)xExp~CH17-360D5.2~+(−0.0683)xExp~LINC00987~+(−6.0924) xExp~LINC01526~+(−3.6727)xExp~RP11-15A1.3~+(−4.9249)xExp~RP11-213H15.1~ +(−0.1602)xExp~RP11-218F4.1~+(−3.7582)xExp~RP11-242F11.2~+(−0.0093) xExp~RP11-411H5.1~+(7.8606)xExp~RP11-834C11.5~.

### Verification of the lncRNA risk assessment model

All samples in the training set were divided into high-risk (n=26) and low-risk (n=27) groups based on the median risk score. The log-rank test indicated that the survival ratio of the high-risk group was significantly increased compared with that of the low-risk group (P=3.532×10^−5^; [Fig. 3A](#f3-mmr-19-02-1128){ref-type="fig"}). The area under the curve (AUC) was 0.926, suggesting a good prognosis prediction ability of the risk assessment system ([Fig. 3A](#f3-mmr-19-02-1128){ref-type="fig"}).

In the validation set, the samples were divided into high-risk (n=18) and low-risk (n=18) groups based on the median risk score. The log-rank test also indicated a markedly increased survival ratio of the high-risk group compared with the low-risk group (P=0.032; [Fig. 3B](#f3-mmr-19-02-1128){ref-type="fig"}). The AUC for the ROC curve based on the risk assessment system was 0.896 ([Fig. 3B](#f3-mmr-19-02-1128){ref-type="fig"}). In the validation set, the RP11-411H5.1, RP11-834C11.5 and LINC00987 were significantly upregulated in the samples belonging to the high-risk group (P\<0.005; [Fig. 4](#f4-mmr-19-02-1128){ref-type="fig"}). The other 6 lncRNAs (LINC01526, RP11-15A1.3, RP11-213H15.1, RP11-218F4.1, RP11-242F11.2 and CH17-360D5.2) were significantly downregulated in the samples belonging to the high-risk group (P\<0.05; [Fig. 4](#f4-mmr-19-02-1128){ref-type="fig"}).

### Risk score is an independent prognostic factor for osteosarcoma

Univariate and multivariate Cox regression analyses were conducted to investigate potential associations between the independent prognostic factors and prognosis. In the training set, risk score \[P=3.530×10^−5^; 95% confidence interval (CI), 2.492--13.030\]; age (P=0.038; 95% CI, 0.134--0.985), grade (P=0.011; 95% CI, 1.284--1.867) and tumor metastasis (P=2.380×10^−7^; 95% CI, 1.963--3.649) were identified to be significantly associated with the prognosis according to the univariate Cox regression analysis. In addition, the multivariate Cox regression analysis demonstrated that risk score (P=0.028; 95% CI, 1.563--5.785), grade (P=0.01; 95% CI, 1.291--1.872) and tumor metastasis (P\<0.001; 95% CI, 1.694--5.312) were identified as independent prognostic factors for osteosarcoma ([Table III](#tIII-mmr-19-02-1128){ref-type="table"}). The effect of risk score on prognosis was then analyzed using a hierarchical analysis, and it was indicated that patients without tumor metastasis in the low-risk group (P=1.249×10^−3^) and high-risk group (P=0.005) exhibited significantly improved prognoses ([Fig. 5](#f5-mmr-19-02-1128){ref-type="fig"}).

### Functional enrichment of prognosis-associated genes

A total of 250 differentially expressed genes, including 232 upregulated and 18 downregulated, were identified among the genes that were associated with the 9 lncRNAs identified using the risk assessment model. The top 10s upregulated \[ribosomal protein lateral stalk subunit P1 (*RPLP1*), ubiquinol-cytochrome c reductase hinge protein (*UQCRH*), prothymosin alpha (*PTMA*), ribosomal protein L23 (*RPL23*), small ubiquitin-like modifier 2, prostaglandin E synthase 3, NADH:ubiquinone oxidoreductase subunit B9 (*NDUFB9*), ribosomal protein L27a (*RPL27A*), karyopherin subunit alpha 2 (*KPNA2*) and ARP3 actin related protein 3 homolog\] and downregulated \[complement C1s (*C1S*), interferon induced protein 44 like, fibroblast activation protein alpha, cytochrome P450 family 27 subfamily A member 1 (*CYP27A1*), CD163 molecule (*CD163*), ETS variant 5, syndecan 1 (*SDC1*), major histocompatibility complex, class II, DM alpha (*HLA-DMA*), C-C motif chemokine ligand 8 (*CCL8*) and monooxygenase DBH like 1\] differentially expressed genes are listed in [Table IV](#tIV-mmr-19-02-1128){ref-type="table"}.

Furthermore, biological processes and signaling pathways were enriched for these 250 prognosis-associated genes. For the biological process (BP) terms, genes were primarily enriched in the translation (including *RPLP1, RPL23* and *RPL27A*; P=2.080×10^−4^), protein transport (including *RPL23* and *HLA-DMA*; P=7.654×10^−3^), inflammatory response (including *C1S* and *CD163*; P=1.26×10^−2^), oxidation reduction (including *UQCRH, NDUFB9* and *CYP27A1*; P=2.148×10^−2^). KEGG pathway enrichment analysis suggested that these genes were primarily enriched in Ribosome (including *RPLP1, RPL23* and *RPL27A*; P=6.270×10^−7^), Oxidative phosphorylation (including *UQCRH* and *NDUFB9*; P=1.355×10^−3^), Glycolysis/Gluconeogenesis \[lactate dehydrogenase B (*LDHB*), phosphoglycerate mutase family member 4 (*PGAM4*), aldolase, fructose-biphosphate C (*ALDOC*), dihydrolipoamide dehydrogenase (*DLD*) and dihydrolipoamide S-acetyltransferase (*DLAT*); P=2.965×10^−3^) and Cell adhesion molecules (CAMs) (including *SDC1* and *HLA-DMA*; P=4.839×10^−2^). The functional and pathway enrichment analyses indicated that TTK protein kinase (*TTK*), cyclin B1 (*CCNB1*) and BUB1 mitotic checkpoint serine/threonine kinase (*BUB1*) were markedly implicated in the cell cycle ([Table V](#tV-mmr-19-02-1128){ref-type="table"}).

Discussion
==========

A total of 211 differentially expressed lncRNAs were identified, and 9 of them (CH17-360D5.2, LINC00987, LINC01526, RP11-15A1.3, RP11-213H15.1, RP11-218F4.1, RP11-242F11.2, RP11-411H5.1 and RP11-834C11.5) were selected to establish a risk assessment model for evaluating the prognosis of patients with osteosarcoma. In the training and validation sets selected, samples with low expression of RP11-411H5.1, RP11-834C11.5 or LINC00987 exhibited significantly increased survival ratios, and samples with increased expression levels of LINC01526, RP11-15A1.3, RP11-213H15.1, RP11-218F4.1, RP11-242F11.2 or CH17-360D5.2 exhibited significantly higher survival ratios.

The ROC curves revealed that this risk assessment model may serve as a good prognostic prediction system in the training (AUC=0.926) and validation sets (AUC 0.896). Furthermore, the risk score calculated based on the expression levels of these 9 lncRNAs was revealed to be an independent prognostic factor for osteosarcoma. Additionally, 250 differentially expressed genes associated with the 9 lncRNAs in the risk assessment model were identified. Functional enrichment analysis for these differentially expressed genes revealed that *UQCRH* and *NDUFB9* were significantly associated with oxidation reduction and oxidative phosphorylation. The gene product of *UQCRH* is a subunit of the respiratory chain protein ubiquinol cytochrome c reductase. *NDUFB9* (22 kDa) is an accessory subunit of the mitochondrial complex I NADH dehydrogenase in the membrane respiratory chain ([@b23-mmr-19-02-1128]). Mutations in mitochondrial DNA or nuclear genes encoding mitochondrial proteins may lead to mitochondrial dysfunctions, which are essential for the respiratory chain/oxidative phosphorylation system ([@b24-mmr-19-02-1128]). It has been suggested that aberrations in mitochondrial complex I NADH dehydrogenase activity may markedly promote breast cancer progression ([@b25-mmr-19-02-1128]). Normal differentiated cells primarily use mitochondrial oxidative phosphorylation to generate energy for cellular processes, whereas cancer cells rely on aerobic glycolysis to generate energy for enhanced growth ([@b26-mmr-19-02-1128],[@b27-mmr-19-02-1128]). In the present study, the pathway enrichment analysis revealed that *LDHB, PGAM4, ALDOC, DLD* and *DLAT* were involved in the glycolysis/gluconeogenesis pathway. Therefore, the lncRNAs in the risk assessment model may target the *UQCRH* and *NDUFB9* to regulate the oxidation reduction, oxidative phosphorylation and glycolysis/gluconeogenesis which are important for the improved growth of osteosarcoma cells.

The functional and pathway enrichment analyses indicated that *TTK, CCNB1* and *BUB1* were markedly implicated in the cell cycle. Huang *et al* ([@b28-mmr-19-02-1128]) demonstrated that *FKBP14* overexpression may promote osteosarcoma carcinogenesis and be associated with poor prognosis. Threonine and tyrosine protein kinase (TTK), also known as the human monopolar spindle 1, is a dual serine/ threonine and tyrosine protein kinase ([@b29-mmr-19-02-1128]). It has been revealed that the suppressed TTK expression identified in osteosarcoma cell lines may significantly decrease the cell proliferation and migration ([@b30-mmr-19-02-1128]). In the study of Huang *et al* ([@b28-mmr-19-02-1128]), *FKBP14* knockdown markedly decreased cell cycle associated CCNB1 protein expression. An additional study indicated that the abundance of CCNB1 mRNA and protein is increased normally from G1 to G2 phase ([@b31-mmr-19-02-1128]). Budding uninhibited by benzimidazoles 1, the product of *BUB1*, is required for accurate chromosome segregation during mitosis. Upregulation and hyper-phosphorylation of *BUB1* may promote malignant transformation in SV40 Tag-induced transgenic mouse models ([@b32-mmr-19-02-1128]). Therefore, the lncRNAs in the risk assessment model may promote progression of osteosarcoma by targeting *TTK, CCNB1* and *BUB1* to affect cell cycle.

In patients with cancer, complex signaling pathways affect survival and prognosis, with metastasis being the major cause of morbidity and mortality and accounting for \~90% of cancer mortalities ([@b33-mmr-19-02-1128]). Metastasis includes an essential step of adhesion and it is affected by the surrounding extracellular matrix (ECM) ([@b34-mmr-19-02-1128]). Focal adhesion is a prerequisite for cellular motility, which is essential to cancer metastasis, and is also involved in the settling of metastatic cancer cells at a distal site ([@b35-mmr-19-02-1128]). Focal adhesion is commonly achieved by connecting the cellular cytoskeleton with ECM components or by connecting adjoining intracellular cytoskeletons ([@b34-mmr-19-02-1128]). Focal adhesion expression has been suggested to be associated with cell migration and normally indicates a poor prognosis ([@b36-mmr-19-02-1128]). Focal adhesion and the ECM have been commonly associated in osteosarcomas, with these factors investigated as potential antitumor targets ([@b37-mmr-19-02-1128],[@b38-mmr-19-02-1128]). In the present study, 4 differentially expressed genes (*ALCAM, SDC1, CDH2* and *HLA-DMA*) associated with the 9 lncRNAs in the risk assessment model were significantly involved in CAMs. Therefore, the lncRNAs in the risk assessment model may have important roles in the progression of osteosarcoma by targeting *ALCAM, SDC1, CDH2* and *HLA-DMA* to regulate the cell adhesion molecules.

In the present study, a risk assessment model was established based on 9 differently expressed lncRNAs and exhibited the potential to be used for assessing prognosis in patients with osteosarcoma. The differentially expressed genes associated with the 9 lncRNAs in this risk assessment model were identified to be associated with oxidation reduction, oxidative phosphorylation, glycolysis/gluconeogenesis, cell cycle and cell adhesion molecules. The results presented in the present study may provide additional insight into the mechanisms of osteosarcoma tumorigenesis. However, certain limitations in the present study remain, including sample size. In addition, the 9 identified potential prognostic lncRNAs require additional experimental validation to fully assess their predictive prognosis abilities in an independent cohort of patients with osteosarcoma.
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![Significantly differentially expressed lncRNAs identified in the training set. Volcanic maps of differentially expressed lncRNAs identified via (A) Student\'s t-test or (B) Wilcoxon rank test. The abscissa indicates the log2 FC and the ordinate indicates the negative logarithm of the P-value. Red nodes indicate upregulated lncRNA, green nodes represent downregulated lncRNA and black nodes represent non-differentially expressed lncRNA. (C) Overlapping differentially expressed lncRNAs between the Student\'s t-test and Wilcoxon rank test. (D) A two-way hierarchical clustering map based on the 211 differentially expressed lncRNAs. FC, fold change; lncRNA, long non-coding RNA.](MMR-19-02-1128-g00){#f1-mmr-19-02-1128}

![Kaplan-Meier curves of overall survival for the 9 long non-coding RNAs in the risk assessment model. The red lines indicate samples with high expression levels and green lines indicate samples with low expression levels.](MMR-19-02-1128-g01){#f2-mmr-19-02-1128}
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![Expression levels for the 9 selected long non-coding RNAs in the validation set. \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.005.](MMR-19-02-1128-g03){#f4-mmr-19-02-1128}
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###### 

Clinical information for training and validation sets.

  Variable                            GSE21257 (n=53)   GSE39055 (n=37)   P-value
  ----------------------------------- ----------------- ----------------- --------------------------------------------------------
  Age (mean ± SD)                     18.71±12.19       13.47±11.34       0.0402^[a](#tfn2-mmr-19-02-1128){ref-type="table-fn"}^
  Sex (male/female)                   34/19             20/17             0.4572^[b](#tfn3-mmr-19-02-1128){ref-type="table-fn"}^
  Metastases (yes/no)                 34/19             --                --
  Death (dead/alive)                  23/30             10/27             0.1728^[b](#tfn3-mmr-19-02-1128){ref-type="table-fn"}^
  Overall survival time (mean ± SD)   68.55±59.34       52.92±50.14       0.1813^[a](#tfn2-mmr-19-02-1128){ref-type="table-fn"}^

SD, standard deviation

Student\'s t-test

Chi-square test.

###### 

Information of 9 lncRNAs screened from the 53 osteosarcoma samples in GSE21257 to build the risk assessment model.

  Long non-coding RNA   Coefficient   Hazard ratio   95% confidence interval   P-value
  --------------------- ------------- -------------- ------------------------- ---------
  CH17-360D5.2          −2.037        0.112          0.042--0.301              0.005
  LINC00987             −0.068        0.111          0.067--0.186              0.037
  LINC01526             −6.092        0.160          0.023--0.213              0.016
  RP11-15A1.3           −3.673        0.107          0.092--0.125              0.024
  RP11-213H15.1         −4.925        0.163          0.035--0.752              0.034
  RP11-218F4.1          −0.160        0.607          0.301--0.802              0.028
  RP11-242F11.2         −3.758        0.781          0.296--0.964              0.013
  RP11-411H5.1          −0.009        0.243          0.219--0.629              0.028
  RP11-834C11.5           7.861       3.510          1.090--4.113              0.016

lncRNA, long non-coding RNA.

###### 

Univariate and multivariate Cox regression analysis for independent prognostic factors of osteosarcoma according to the 53 osteosarcoma samples in the GSE21257 data set.

                              Univariate analysis   Multivariate analysis                                        
  --------------------------- --------------------- ----------------------- ------------- ------- -------------- -------------
  Risk score (high/low)       7.574                 2.492--13.030           3.53×10^−5^   1.868   1.563--5.785   0.028
  Age (\<18/≥18)              0.363                 0.134--0.985            0.038         0.738   0.228--2.386   0.814
  Sex (male/female)           1.403                 0.588--3.348            0.444         --      --             --
  Grade (G1+G2/G3+G4)         1.496                 1.284--1.867            0.011         1.504   1.291--1.872   0.014
  Tumor metastases (yes/no)   2.218                 1.963--3.649            2.38×10^−7^   1.211   1.037--2.759   2.71×10^−3^

HR, hazard ratio; CI, confidence interval.

###### 

Top 10 upregulated and downregulated differentially expressed genes associated with the 9 lncRNAs in the risk assessment model.

  A, Upregulated genes                                      
  ----------------------------- ------------ -------------- --------------
  RPLP1                         1.331        1.860×10^−6^   1.305×10^−4^
  UQCRH                         1.298        7.820×10^−7^   5.480×10^−5^
  PTMA                          1.293        6.750×10^−6^   4.734×10^−4^
  RPL23                         1.237        4.850×10^−6^   3.399×10^−4^
  SUMO2                         1.209        6.110×10^−6^   4.281×10^−4^
  PTGES3                        1.165        6.770×10^−6^   4.743×10^−4^
  NDUFB9                        1.133        1.110×10^−6^   7.790×10^−5^
  RPL27A                        1.131        1.520×10^−6^   1.068×10^−4^
  KPNA2                         1.108        3.180×10^−6^   2.228×10^−4^
  ACTR3                         1.061        4.780×10^−6^   3.348×10^−4^
                                                            
  **B, Downregulated. genes**                               
                                                            
                                **Log FC**   **P-value**    **FDR**
                                                            
  C1S                           −0.501       6.443×10^−4^   4.517×10^−2^
  IFI44L                        −0.503       4.218×10^−4^   2.957×10^−2^
  FAP                           −0.506       4.576×10^−4^   3.208×10^−2^
  CYP27A1                       −0.513       4.440×10^−6^   3.110×10^−4^
  CD163                         −0.526       1.821×10^−4^   1.277×10^−2^
  ETV5                          −0.526       3.940×10^−6^   2.759×10^−4^
  SDC1                          −0.528       1.390×10^−5^   9.719×10^−4^
  HLA-DMA                       −0.535       3.650×10^−5^   2.559×10^−3^
  CCL8                          −0.537       4.822×10^−4^   3.380×10^−2^
  MOXD1                         −0.574       5.927×10^−4^   4.155×10^−2^

FC, fold change; FDR, false discovery rate.

###### 

Significantly enriched functions and pathways for the identified prognosis-associated genes.

  Category   Term                                                                 Count   P-value        Genes
  ---------- -------------------------------------------------------------------- ------- -------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------
  BP         GO:0006414; translational elongation                                 11      3.690×10^−6^   *RPS28, RPL23, RPL14, RPL7, RPS3A, RPLP1, RPS15, RPL27A, RPL23A, RPL7A, RPL10A*
  BP         GO:0006412; translation                                              16      2.080×10^−4^   *MRPL51, CARS, RPL14, NARS, RPL27A, RPL23A, RPS28, RPL7, RPL23, RPS3A, EIF1AX, RPS15, RPLP1, MRPL19, RPL10A, RPL7A*
  BP         GO:0006091; generation of precursor metabolites and energy           14      1.223×10^−3^   *UQCRC2, TXNL1, LDHB, NDUFB10, ALDOC, NDUFB9, DLAT, SLC25A13, UQCRH, PGAM4, SDHD, DLD, UQCRB, FH*
  BP         GO:0008283; cell proliferation                                       16      3.357×10^−3^   *MORF4L1, COPS2, STIL, PDPN, VTI1B, IFI16, RBBP7, GAS6, LGR4, SBDS, GOLPH3, PCNA, CKS2, BUB1, RAP1B, ASPM*
  BP         GO:0070271; protein complex biogenesis                               17      5.484×10^−3^   *TCP1, MSTO1, ALDOC, CAPZA1, GJA1, ANLN, CDH2, CENPJ, HLA-DMA, PICALM, UQCRH, GOPC, NPM1, PDGFC, ANGPT1, KPNA3, KPNB1*
  BP         GO:0006461; protein complex assembly                                 17      5.484×10^−3^   *TCP1, MSTO1, ALDOC, CAPZA1, GJA1, ANLN, CDH2, CENPJ, HLA-DMA, PICALM, UQCRH, GOPC, NPM1, PDGFC, ANGPT1, KPNA3, KPNB1*
  BP         GO:0015031; protein transport                                        22      7.654×10^−3^   *GDI2, GOLT1B, VTI1B, PPT1, CLTC, HLA-DMA, TIMM8B, RAB33B, NXT2, YWHAG, RPL23, RAB18, GOPC, NPM1, PCNA, YIPF5, KPNA3, KPNA2, SAR1A, SEC24D, KPNB1, NMD3*
  BP         GO:0045184; establishment of protein localization                    22      8.450×10^−3^   *GDI2, GOLT1B, VTI1B, PPT1, CLTC, HLA-DMA, TIMM8B, RAB33B, NXT2, YWHAG, RPL23, RAB18, GOPC, NPM1, PCNA, YIPF5, KPNA3, KPNA2, SAR1A, SEC24D, KPNB1, NMD3*
  BP         GO:0009611; response to wounding                                     17      8.564×10^−3^   *A2M, NMI, PDPN, CCL8, C1S, CD163, CCNB1, HDAC4, PLSCR1, CD55, SDC1, STAB1, MTPN, SERPINE1, VSIG4, CD14, NFX1*
  BP         GO:0006954; inflammatory response                                    12      1.264×10^−2^   *HDAC4, A2M, CD55, NMI, PDPN, STAB1, CCL8, C1S, VSIG4, CD14, CD163, NFX1*
  BP         GO:0065003; macromolecular complex assembly                          19      1.558×10^−2^   *TCP1, MSTO1, ALDOC, CAPZA1, GJA1, ANLN, CDH2, CENPJ, HLA-DMA, SMNDC1, PICALM, UQCRH, GOPC, RPS15, NPM1, PDGFC, ANGPT1, KPNA3, KPNB1*
  BP         GO:0007049; cell cycle                                               21      1.796×10^−2^   *PDPN, GMNN, TTK, ANLN, RBM7, CDC5L, UBE2C, CENPJ, MLF1, CCNB1, SBDS, GADD45GIP1, PSMA6, FANCD2, NPM1, CKS2, BUB1, KPNA2, MCTS1, ASPM, CDCA3*
  BP         GO:0055114; oxidation reduction                                      18      2.148×10^−2^   *UQCRC2, TXNL1, LDHB, NDUFB10, CYP51A1, NDUFB9, UGDH, MOXD1, MTRR, FDFT1, MTHFD2, SLC25A13, CYP27A1, P4HA1, UQCRH, DLD, SDHD, UQCRB*
  BP         GO:0043933; macromolecular complex subunit organization              19      2.790×10^−2^   *TCP1, MSTO1, ALDOC, CAPZA1, GJA1, ANLN, CDH2, CENPJ, HLA-DMA, SMNDC1, PICALM, UQCRH, GOPC, RPS15, NPM1, PDGFC, ANGPT1, KPNA3, KPNB1*
  BP         GO:0022402; cell cycle process                                       16      3.030×10^−2^   *TTK, ANLN, RBM7, UBE2C, CENPJ, MLF1, CCNB1, SBDS, PSMA6, FANCD2, NPM1, CKS2, BUB1, KPNA2, ASPM, CDCA3*
  BP         GO:0006886; intracellular protein transport                          12      3.190×10^−2^   *YWHAG, RPL23, NPM1, PCNA, VTI1B, CLTC, KPNA3, KPNA2, SAR1A, KPNB1, SEC24D, TIMM8B*
  BP         GO:0000279; M phase                                                  11      3.283×10^−2^   *CCNB1, FANCD2, BUB1, CKS2, TTK, RBM7, ANLN, UBE2C, KPNA2, ASPM, CDCA3*
  BP         GO:0008104; protein localization                                     22      3.337×10^−2^   *GDI2, GOLT1B, VTI1B, PPT1, CLTC, HLA-DMA, TIMM8B, RAB33B, NXT2, YWHAG, RPL23, RAB18, GOPC, NPM1, PCNA, YIPF5, KPNA3, KPNA2, SAR1A, SEC24D, KPNB1, NMD3*
  BP         GO:0010605; negative regulation of macromolecule metabolic process   19      3.693×10^−2^   *IBTK, COPS2, BTAF1, A2M, MTDH, GMNN, FZD1, HAT1, RBBP7, UBE2C, HDAC4, SAP30, HDAC2, PSMA6, HEY1, PRKRA, NPM1, DNAJC1, NFX1*
  PATHWAY    hsa03010; ribosome                                                   11      6.270×10^−7^   *RPS28, RPL23, RPL14, RPL7, RPS3A, RPLP1, RPS15, RPL27A, RPL23A, RPL7A, RPL10A*
  PATHWAY    hsa00190; oxidative phosphorylation                                  8       1.355×10^−3^   *UQCRC2, NDUFB10, UQCRH, NDUFB9, SDHD, COX7B, PPA2, UQCRB*
  PATHWAY    hsa04260; cardiac muscle contraction                                 6       1.810×10^−3^   *UQCRC2, ATP1B3, UQCRH, TNNC1, COX7B, UQCRB*
  PATHWAY    hsa00010; glycolysis/Gluconeogenesis                                 5       2.965×10^−3^   *LDHB, PGAM4, ALDOC, DLD, DLAT*
  PATHWAY    hsa04110; cell cycle                                                 7       3.570×10^−3^   *CCNB1, YWHAG, HDAC2, BUB1, PCNA, TTK, RBX1*
  PATHWAY    hsa04610; complement andcoagulation cascades                         4       1.536×10^−2^   *A2M, CD55, SERPINE1, C1S*
  PATHWAY    hsa04142; lysosome                                                   4       4.059×10^−2^   *CTSO, PPT1, CD164, CLTC*
  PATHWAY    hsa03040; spliceosome                                                4       4.532×10^−2^   *HSPA1A, CDC5L, PRPF18, SMNDC1*
  PATHWAY    hsa04514; cell adhesion molecules                                    4       4.839×10^−2^   *ALCAM, SDC1, CDH2, HLA-DMA*

BP, biological process.
